Anavex Life Sciences Corp (AVXL)

[ElsaSara]

Anavex Life Sciences Announces First Patient Dosed in Extension Study to its U.S. Phase 2 Clinical Trial of ANAVEX®2-73 in Patients for Rett Syndrome

GlobeNewswireJune 25, 2019, 1:00 PM GMT+2

NEW YORK, June 25, 2019 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today announced that the first patient, who completed the Phase 2 clinical trial ANAVEX®2-73-RS-001 voluntarily moved into the extension study and was dosed in the extension study for the treatment of Rett syndrome.

The open label, 12 week extension study is designed to evaluate long term safety, tolerability, and the effect of ANAVEX®2-73 on Rett syndrome patients following the completion of the Phase 2 study.

Patients who are eligible to be enrolled in the extension study are those who have completed 7 weeks of treatment in the ANAVEX®2-73-RS-001 trial in the U.S.

All eligible patients will be treated with oral liquid ANAVEX®2-73 formulation given once daily for additional 12 weeks. The extension study might be further extended.

ANAVEX®2-73 has already received orphan drug designation from the FDA for the treatment of Rett syndrome.

“We are delighted to provide continuation of ANAVEX®2-73 treatment for Rett syndrome patients. This study is part of an Anavex Rett syndrome program including further studies of ANAVEX®2-73, among them an ongoing Phase 2 study overseas1,” said Christopher U Missling, PhD, President and Chief Executive Officer of Anavex. “In addition to Rett syndrome, Anavex has ongoing clinical development programs for ANAVEX®2-73 for the treatment of Alzheimer’s disease2 and Parkinson’s disease dementia3.”